Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Axsome Thera
(NQ:
AXSM
)
74.80
+0.61 (+0.82%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Axsome Thera
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
April 30, 2024
Here are our top three choices for biotech stocks with blockbuster drug pipelines that could pay off massively in the future.
Via
InvestorPlace
Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
April 29, 2024
Via
Benzinga
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
April 16, 2024
Stocks that work for billionaires aren't necessarily appropriate for every investor.
Via
The Motley Fool
Analyst Ratings For Axsome Therapeutics
April 10, 2024
Via
Benzinga
2 Under-the-Radar Growth Stocks to Consider
April 10, 2024
Don't ignore these innovative companies.
Via
The Motley Fool
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
March 27, 2024
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.
Via
InvestorPlace
What Analysts Are Saying About Axsome Therapeutics Stock
March 19, 2024
Via
Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
February 27, 2024
Via
Benzinga
Earnings Outlook For Axsome Therapeutics
February 19, 2024
Via
Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
March 26, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
March 25, 2024
Unlock insights from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. AXS-12 demonstrated significant reductions in cataplexy attacks, improved daytime wakefulness, and...
Via
Benzinga
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
March 23, 2024
The price could be right for these three biopharma stocks.
Via
The Motley Fool
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
February 26, 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential.
Via
InvestorPlace
3 Biotech Stocks to Buy and Hold for the Next 10 Years
February 26, 2024
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.
Via
The Motley Fool
The Latest Analyst Ratings For Axsome Therapeutics
February 06, 2024
Via
Benzinga
The Analyst Landscape: 6 Takes On Axsome Therapeutics
January 16, 2024
Via
Benzinga
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
February 20, 2024
AXSM earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
February 20, 2024
Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth.
Via
Benzinga
Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug
February 20, 2024
The company is testing a treatment for patients with agitation due to Alzheimer's disease.
Via
Investor's Business Daily
2 Stocks That Could Double Your Money in 5 Years
February 08, 2024
These market-beating stocks could be just getting started.
Via
The Motley Fool
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
February 06, 2024
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.
Via
Benzinga
Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own'
January 26, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. (NYSE: BLK).
Via
Benzinga
Earnings Scheduled For February 20, 2024
February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion.
Via
Benzinga
Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says
January 25, 2024
Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates.
Via
Benzinga
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
January 23, 2024
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years
January 03, 2024
Is it too late to invest in these fast-growing stocks?
Via
The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
January 02, 2024
The types of innovative drugs these companies develop are always in high demand.
Via
The Motley Fool
Prediction: These 3 Stocks Will Soar in 2024
January 01, 2024
Investors could enjoy an especially happy new year with these great stocks.
Via
The Motley Fool
3 Unstoppable Stocks to Buy Right Now
December 10, 2023
These stocks could be just the ticket for investors seeking strong growth.
Via
The Motley Fool
3 Biotech Stocks That Could Be Millionaire Makers
November 22, 2023
Many biotech stocks offer exciting long-term growth prospects.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.